Friday, September 30, 2022

561.316.3330

Biotechnology News Magazine

Sinocompound Announces Commercial-scale Production of QPhos Ligand

Latest Posts

City of Hope to Accelerate Immunotherapy Research & Treatment Innovation with $15 Mil Gift from Ted Schwartz Family

Ted Schwartz, who is now cancer free, achieved complete remission at City of Hope in 2020 with the center's leading CAR T cell therapy after a 16-year battle with lymphoma, provided the gift to City of Hope to advance treatment options that offer better outcomes and quality of life for people living with cancer.

Neurocrine Biosciences Appoints Dr Ingrid Delaet as Chief Regulatory Officer

Prior to joining Neurocrine Biosciences, Dr Ingrid Delaet served as Senior Vice President, Regulatory Affairs at Intercept Pharmaceuticals, which she joined in 2016.

Astrea Bioseparations Introduces Nereus LentiHERO, a Fit-for-purpose Solution for Lentiviral Vector Purification

“We believe that AstreAdept will be a game-changer,” explained Astrea Bioseparations’ CEO Terry Pizzie. “Our approach was to rapidly develop and incorporate this material into the Nereus LentiHERO, a simple, fit-for-purpose device that radically transforms how lentivirus can be purified [in terms of speed, recovery, and efficiency].

At Pack Expo, Schreiner MediPharm to Debut Functional Labels Designed from More Sustainable Materials

Schreiner MediPharm advises he new label concepts are based on existing items in Schreiner MediPharm’s roster of functional labeling solutions.

Sinocompound Catalysts Co., Ltd, a global provider of advanced homogeneous catalysts and ligands, has announced production of the phosphine-based QPhos ligand in kilogram quantities for commercial use.

With this ligand now accessible on a large scale, scientists across the globe can incorporate QPhos-based catalysts in their drug discovery, screening and process development programs to optimize and streamline their product development phase.

Pharmaceutical companies invest significantly in drug development to optimize product synthesis and expedite their innovations to market. QPhos is a promising ligand in metal-catalyzed cross-coupling reactions, which are fundamental to construct carbon-based bonds featured in most drug scaffolds. However, until now QPhos has not been readily available in commercial quantities, hindering its adoption in process development and scale-up programs.

“There’s an enormous amount of untapped potential in ligands that scientists simply can’t access on a large scale, so they discount them from their screening programs,” says Dr Carin Seechurn, Associate Director – Technology Solutions, Sinocompound. “Our capability to scale-up the QPhos ligand represents a significant milestone in improving ligand accessibility for researchers. As we continue to expand our manufacturing processes thanks to our new plant in Tongling, we’re excited to provide more overlooked ligands and products commercially.”

QPhos is a robust dialkylarylphosphine ligand developed by Professor John Hartwig for metal-catalyzed cross-coupling reactions[i]. Bulky and electron-rich, it performs excellently in many transformations including α-arylation of carbonyl compounds and late-stage C-C bond formation.

[i] N. Kataoka, Q. Shelby, J. P. Stambuli, J. F. Hartwig, J. Org. Chem. 2002, 67, 16, 5553–5566.

Latest Posts

Learn More

spot_img

Subscribe

spot_img

Our Sister Publication

Medical Device News Magazine